Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al. Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al.
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
Experience
Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc. Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc.
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
Experience
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al. Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
Experience
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
Experience
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Experience
Innovacell AG v. University of Pittsburgh* Innovacell AG v. University of Pittsburgh*
T 0527/17, EPO
Experience
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al. Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Experience
Finnegan secures $180M for CSRC in complex arbitrations Finnegan secures $180M for CSRC in complex arbitrations
01-19-0001-6937; 01-20-0000-5081, American Arbitration Association (AAA)
Experience
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc. Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.
1:21-cv-01015, D. Del., Judges Hall, Williams
Experience
Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same
337-TA-1238, ITC, Judge McNamara
Experience
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al. Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
1:20-cv-01226, D. Del., Judge Andrews
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.